Clinical Trials Browser

Phase 1/2 × Melanoma × Bortezomib × Clear all

NCT00512798 2012-10-02

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Phase 1/2 Terminated

47 enrolled 9 charts

CNSDermatologic

Brain Neoplasms, Melanoma, Central Nervous System Neoplasms